Exelixis and Teva Settle
Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license
SG Tylor
Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...
